| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9600980 | Clinical Oncology | 2005 | 5 Pages |
Abstract
In this small phase-II study, gemcitabine demonstrated a high anti-tumoural activity in SCCHN, with a favourable toxicity profile. Gemcitabine seems to be a promising new drug without severe burden even for patients who are refractory to other cytostatic drugs. Within recent years, the activity and tolerability of gemcitabine was documented in several phase I and phase II trials, especially in combination with cisplatin, and paclitaxel resp, carboplatin/paclitaxel, cisplatin/ifosfamide, and 5-fluorouracil/paclitaxel. The results of these trials will be outlined in the discussion.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
J.D. Raguse, H.J. Gath, J. Bier, H. Riess, H. Oettle,